BC Cancer Agency – Oral Cancer News

Verisante Technology, Inc. Announces Completion of Prototype of Multispectral Imaging System for Skin Cancer

Source: MarketWatchPublished: September 10, 2013 VANCOUVER, BRITISH COLUMBIA, Sep 10, 2013 (Marketwired via COMTEX) -- Verisante Technology, Inc. CA:VRS -4.84% (otcqx:VRSEF) (the "Company" or "Verisante"), a leader in cancer detection technology, announced today that the Company has completed the second phase prototype of a rapid Multispectral Imaging ("MSI") System for skin cancer detection. The MSI device is intended to assist medical professionals in the detection of all major forms of skin cancer. The device takes images of suspicious lesions with more than a dozen different wavelengths of light to capture real-time spectral images in a fraction of a second. These spectral images contain unique information about suspected skin lesions such as tissue oxygenation ratios, hemoglobin levels, melanin levels, scatter sizes, and other parameters. The prototype system is currently undergoing laboratory testing at the BC Cancer Agency Research Centre prior to starting in vivo data collection for training the predictive algorithm for the device. "Being able to extract the parameters collected by this MSI system could provide a strong predictive measurement for all major forms of skin cancer," said Dr. Haishan Zeng, a distinguished scientist in the Integrative Oncology Department at the BC Cancer Agency. Verisante licensed the MSI technology from the inventors, Dr. Haishan Zeng and Dr. Yasser Fawzy of the BC Cancer Agency, for skin cancer and oral cancer detection as part of a broader acquisition strategy to enhance the Company's intellectual property portfolio of different technologies that, in addition to MSI, include white light reflectance imaging, fluorescence imaging [...]

Charlotte Parker2013-09-11T14:01:00-07:00September, 2013|Oral Cancer News|

Blue light tool could save lives of patients suffering from oral cancer

Source: www.google.com/hostednews/canadianpress Author: Camille Bains, The Canadian Press A device that emits a blue light is giving patients undergoing surgery for oral cancer a fighting chance at survival and Canada is at the forefront of research that could have a global impact, researchers say. Doctors and scientists in nine Canadian cities began testing the tool last September as part of a five-year study on 400 patients who are suffering from cancer that has afflicted their tongue or other parts of the mouth. The hand-held fluorescence visualization tool allows surgeons to see cancer cells that can't be detected by conventional white light so they can remove the affected tissue and prevent the disease from recurring. Balvir Dhadda, 47, thought she'd been given a death sentence when she was diagnosed with the deadly disease four years ago after developing a sore underneath the left side of her tongue. "When I got diagnosed, I thought `That's it.'" But Dhadda credits the blue light device for saving her life. "This was the tool used on me, and the rest is history," Dhadda said Thursday. The tool ensured doctors removed only the tissue that was cancerous, rather than the usual practice of removing parts that might potentially be. "I think it was a major factor in the time it took me to recover afterwards," said Dhadda, of Surrey, B.C. Miriam Rosin, the principle investigator of the study, said the blue-light tool developed at the BC Cancer Agency had been used to detect lung, cervical and [...]

Oral Cancer Foundation News Team - A2011-05-27T05:25:36-07:00May, 2011|Oral Cancer News|

Perceptronix Reports Clinical Study Underway to Evaluate OralAdvance(TM) for Early Detection of Oral Cancer

Source: www.earthtimes.org Author: press release Perceptronix Medical Inc. announces that a clinical study of OralAdvance(TM), a test for the early detection of oral cancer, is now underway. The clinical study will assess the performance of OralAdvance(TM) compared to the gold standard biopsy and histology for its ability to differentiate between visually suspicious oral lesions with cancer or pre-cancer and visually suspicious benign oral lesions. "Unlike many other types of cancer, the incidence and mortality rates of oral cancer have not shown significant improvement over the past 30 years. By the time most oral cancers are diagnosed, they are already symptomatic late-stage disease. At Perceptronix we are dedicated to changing this paradigm towards early detection for better patient outcomes," says Dr. Bojana Turic, President and CEO of Perceptronix. Patients for the blinded study will be recruited from the BC Cancer Agency's Vancouver and Fraser Valley Centres. "We are pleased to be able to participate in the evaluation of the test in a clinical setting with technology that was developed in partnership with scientists at the BC Cancer Agency's Research Centre, and we are hopeful that the test will have a positive impact on the early detection of oral cancer," says Dr. Allan Hovan (Provincial Professional Practice Leader, Program in Oral Oncology/Dentistry, BC Cancer Agency). Currently, the death rate for oral cancer is higher than that of cervical cancer, Hodgkin's disease, cancer of the brain, liver, testes, kidney, or malignant melanoma. High death rate associated with oral cancer could be reduced significantly [...]

Oral Cancer Foundation News Team - A2009-05-08T18:56:15-07:00May, 2009|Oral Cancer News|

Perceptronix reports clinical study underway to evaluate OralAdvance(TM) for early detection of oral cancer

Source: www.earthtimes.org Author: press release Perceptronix Medical Inc. announces that a clinical study of OralAdvance(TM), a test for the early detection of oral cancer, is now underway. The clinical study will assess the performance of OralAdvance(TM) compared to the gold standard biopsy and histology for its ability to differentiate between visually suspicious oral lesions with cancer or pre-cancer and visually suspicious benign oral lesions. "Unlike many other types of cancer, the incidence and mortality rates of oral cancer have not shown significant improvement over the past 30 years. By the time most oral cancers are diagnosed, they are already symptomatic late-stage disease. At Perceptronix we are dedicated to changing this paradigm towards early detection for better patient outcomes," says Dr. Bojana Turic, President and CEO of Perceptronix. Patients for the blinded study will be recruited from the BC Cancer Agency's Vancouver and Fraser Valley Centres. "We are pleased to be able to participate in the evaluation of the test in a clinical setting with technology that was developed in partnership with scientists at the BC Cancer Agency's Research Centre, and we are hopeful that the test will have a positive impact on the early detection of oral cancer," says Dr. Allan Hovan (Provincial Professional Practice Leader, Program in Oral Oncology/Dentistry, BC Cancer Agency). Currently, the death rate for oral cancer is higher than that of cervical cancer, Hodgkin's disease, cancer of the brain, liver, testes, kidney, or malignant melanoma. High death rate associated with oral cancer could be reduced significantly [...]

Oral Cancer Foundation News Team - A2009-02-09T16:56:36-07:00February, 2009|Oral Cancer News|